Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement.
BTK inhibitors
Waldenström macroglobulinemia
ibrutinib
real-world
recommendations
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
15
02
2022
received:
16
12
2021
accepted:
18
02
2022
pubmed:
26
2
2022
medline:
10
8
2022
entrez:
25
2
2022
Statut:
ppublish
Résumé
The pivotal role that ibrutinib plays in the management of Waldenström macroglobulinemia (WM) is undisputed but there are ongoing questions regarding its positioning in the therapeutic algorithm of WM as well as in some peculiar clinical situations. A panel of experts from Italy was convened to provide real world recommendations on the use of BTK inhibitors in lymphoproliferative diseases in general, and in patients with WM in particular. This position paper represents the panel's collective analysis, evaluation, and opinions and is made up of a series of questions frequently asked by practicing clinicians and answers based on currently available evidence.
Substances chimiques
Piperidines
0
Protein Kinase Inhibitors
0
Pyrazoles
0
Pyrimidines
0
ibrutinib
1X70OSD4VX
Agammaglobulinaemia Tyrosine Kinase
EC 2.7.10.2
Adenine
JAC85A2161
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
332-340Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012;367(9):826-833.
EMA Advisory Committee Recommends Full Approval of IMBRUVICA® (Ibrutinib) to Treat Waldenstrom's Macroglobulinemia. [Accessed September 2021]. https://www.ewmnetwork.eu
Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenström macroglobulinemia: mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol 2017;3(9):1257-1265.
Dimopoulos MA, Tedeschi A, Trotman J, et al. iNNOVATE study group and the European consortium for Waldenström’s macroglobulinemia. phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018 Jun 21;378(25):2399-2410.
Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol 2017;18:241-250.
Kastritis E, Leblond V, Dimopoulos MA, et al. On behalf of the ESMO Guidelines Committee. Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):860-862.
Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Ann Hematol. 2018;97(8):1417-1425.
Talaulikar D, Advani RH, Branagan AR, et al. Consensus statement on the management of Waldenström macroglobulinemia patients during the COVID-19 pandemic. Hemasphere. 2020;4(4):e433.
Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015;372(15):1430-1440.
Treon SP, Meid K, Gustine J, et al. Long-Term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia. J Clin Oncol. 2021;39(6):565-575.
Buske C, Tedeschi A, Trotman J, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol. 2022;40(1):52-62.
Trotman J, Buske C, Tedeschi A, et al. Long-term follow-up of ibrutinib treatment for rituximab-refractory Waldenström's macroglobulinemia: final analysis of the open-label substudy of the Phase 3 iNNOVATETM trial. Blood. 2020;136(Suppl 1):38-39.
Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström macroglobulinaemia. Lancet Haematol 2020;7(11):827-837.
Castillo JJ, Xu L, Gustine JN, et al. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019;187:356-363.
Castillo JJ, Gustine JN, Meid K, et al. CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020;95:95-98.
Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstrom’s macroglobulinemia with bortezomib. Haematologica. 2005;90:1655-1658.
Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1570-1575.
Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28:1422-1428.
Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, et al. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018;132(24):2608-2612.
Laribi K, Poulain S, Willems L, et al. Bendamustine plus rituximab in newly-diagnosed Waldenstrom macroglobulinemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. 2018;103:1-3.
Treon SP, Lian Xu L, Guerrera ML, et al. Genomic Landscape of Waldenström macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020;38(11):1198-1208.
Castillo JJ, Treon SP. How we manage Bing-Neel syndrome. Br J Haematol. 2019;187:277-285.
Simon L, Lemal R, Fornecker LM, Tournilhac O, Leblond V. High-dose therapy with autologous stem cells transplantation in Bing-Neel syndrome: a retrospective analysis of 14 cases. Am J Hematol. 2019;94(9):227-229.
Varettoni M, Defrancesco I, Diamanti L, Marchioni E, Farina LM, Pichiecchio A. Bing-Neel Syndrome: illustrative cases and comprehensive review of the literature. Mediterr J Hematol Infect Dis. 2017;9(1):e2017061.
Castillo JJ, Itchaki G, Paludo J, et al. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019;133(4):299-305.
Canals C, Sibon D, Cahn jy, et al. High-dose therapy and autologous stem-cell transplantation in waldenstrom macroglobulinaemia: the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2010;28:2227-2232.
Kyriakou C, Canals C, Cornelissen JJ, et al. Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2010;28(33):4926-4934.
Kyriakou C, Advani RH, Ansell SM, et al. Indications for haematopoietic stem cell transplantation in patients with Waldenstrom’s macroglobulinaemia: a consensus project of the EBMT Lymphoma Working Party (LWP)/European Consortium for Waldenstrom’s macroglobulinaemia (ECWM)/International Waldenstrom’s macroglobulinaemia Foundation (IWMF). Blood. 2017;130:2026. (abstrt).
Leblebjian H, Noonan K, Paba-Prada C, et al. Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. Am J Hematol. 2015;90(6):122-123.
Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the eighth International workshop on Waldenström's macroglobulinemia. Blood. 2016;128(10):1321-1328.
Nobile-Orazio E, Manfredini E, Carpo M, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol. 1994;36(3):416-424.
Svahn J, Petiot P, Antoine J-C, et al. Francophone anti-MAG cohort Group, Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry. 2018;89:499-505.
Parisi M, Ferrero B, Bertuzzo A, et al. Abstracts of the 51st annual conference of the Italian society of neurology. Neurol Sci. 2020;41:1-347.
Léger JM, Viala K, Nicolas G, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013;80(24):2217-2225.
Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2016;10(10):CD002827.
Castellani F, Visentin A, Campagnolo M, et al. The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e720.
D’Sa S, Kersten MJ, Castillo JJ, et al. Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017;176:728-742.
Palladini G, Merlini G. Diagnostic challenges of amyloidosis in Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013;13(2):244-246.
Sachchithanantham S, Roussel M, Palladini G, et al. Prognostic criteria in monoclonal immunoglobulin M-related light chain amyloidosis. J Clin Oncol. 2016;34(17):2037-2045.
Palladini G, Foli A, Russo P, et al. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011;11(1):143-145.
Mikhael J, Richardson P, Usmani SZ, et al. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood. 2019;134(2):123-133.
Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387-4390.
Milani P, Schönland S, Merlini G, et al. Treatment of AL amyloidosis with bendamustine: a study of 122 patients. Blood. 2018;132(18):1988-1991.
Pika T, Hegenbart U, Flodrova P, Maier B, Kimmich C, Schönland SO. First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival. Blood. 2018;131(3):368-371.
Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood. 2019;134(23):2022-2035.
Manwani R, Sachchithanantham S, Mahmood S, et al. Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine. Blood. 2018;132:761-764.
Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122(19):3276-3282.
Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol 2020;7:112-121.
[Accessed September 2021]. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3192167
[Accessed September 2021]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-waldenstroms-macroglobulinemia
Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038-2050.
Garcia-Sanz R, Dimopoulos MA, Lee H-P et al. Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM). J Clin Onol 2020;38:(15 Suppl l):20056-20056.
Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14;121(11):2051-2058.
Drandi D, Ferrero S, Ladetto M. Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative disorders. Methods Mol Biol. 2018;1768:229-256.
Varettoni M, Zibellini S, Defrancesco I, et al. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica. 2017;102(12):2077-2085.
Ferrante M, Furlan D, Zibellini S, et al. MYD88L265P Detection in IgM monoclonal gammopathies: methodological considerations for routine implementation. Diagn (Basel). 2021;11(5):779.
Drandi D, Genuardi E, Dogliotti I, et al. Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. Haematologica. 2018;103(6):1029-1037.
Castillo JJ, Libby EN, Ansell SM, et al. Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. Blood Adv. 2020;4(20):5089-5092.